Wells Fargo & Company MN decreased its holdings in shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) by 48.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,704 shares of the biopharmaceutical company’s stock after selling 36,061 shares during the period. Wells Fargo & Company MN owned 0.07% of Tetraphase Pharmaceuticals worth $268,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in TTPH. UBS Group AG boosted its position in shares of Tetraphase Pharmaceuticals by 2.3% during the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 387 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Tetraphase Pharmaceuticals during the 2nd quarter worth approximately $200,000. American International Group Inc. raised its stake in Tetraphase Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,486 shares during the period. JPMorgan Chase & Co. raised its stake in Tetraphase Pharmaceuticals by 88.2% during the 1st quarter. JPMorgan Chase & Co. now owns 23,115 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 10,834 shares during the period. Finally, Rhumbline Advisers raised its stake in Tetraphase Pharmaceuticals by 5.7% during the 2nd quarter. Rhumbline Advisers now owns 51,633 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 2,780 shares during the period. Institutional investors own 42.82% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/19/tetraphase-pharmaceuticals-inc-ttph-shares-sold-by-wells-fargo-company-mn.html.
A number of research firms recently weighed in on TTPH. HC Wainwright upped their price target on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. BMO Capital Markets upped their price target on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Sunday, September 17th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $15.15.
Tetraphase Pharmaceuticals, Inc. (NASDAQ TTPH) opened at $6.88 on Friday. Tetraphase Pharmaceuticals, Inc. has a 52 week low of $3.57 and a 52 week high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). The firm had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company’s quarterly revenue was up 355.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.58) earnings per share. sell-side analysts anticipate that Tetraphase Pharmaceuticals, Inc. will post -2.88 EPS for the current year.
In other news, insider Jacques Dumas sold 8,750 shares of the stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at $52,762.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 5.50% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.